Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. 2006

Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
Department of Hematology, Oncology and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, D-12200, Berlin, Germany. kristoph.jahnke@charite.de

Data on relapsed primary central nervous system lymphoma (PCNSL) are limited. We have evaluated the clinical characteristics and outcome of relapsed PCNSL patients from two German trials. Patients with relapsed disease after primary treatment were studied. Primary therapy consisted of high-dose methotrexate-based chemotherapy in all patients. Treatment for relapse was not predetermined. After a median follow-up of 22.5 months, 52 (36%) patients with relapse were identified among 143 patients with complete remission (CR) after primary treatment. The median disease-free survival was 10.25 (3-47.5) months. The median age at relapse was 59 years. Forty-four of 51 evaluable patients relapsed within the CNS, 6 systemically and one both cerebrally and systemically. The median survival time after first relapse was 4.5 (0.5-40.5) months. Karnofsky performance status (KPS) at relapse (P = 0.004), site of relapse (isolated systemic versus other, P = 0.049) and treatment for relapse (versus no treatment, P = 0.001) were independent prognostic factors for survival after relapse in multivariate analysis. Survival of patients with relapsed PCNSL is poor despite high response rates to salvage therapy. Good KPS, isolated systemic relapse and treatment for relapse were significantly associated with longer survival.

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
March 2012, The Korean journal of hematology,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
May 2001, Zhonghua nei ke za zhi,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
November 2022, Current opinion in oncology,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
January 2020, Asian journal of neurosurgery,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
January 2004, Acta oncologica (Stockholm, Sweden),
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
June 2021, Cancers,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
August 2005, Hematology/oncology clinics of North America,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
May 2007, Leukemia & lymphoma,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
February 2017, Leukemia & lymphoma,
Kristoph Jahnke, and Eckhard Thiel, and Peter Martus, and Ulrich Herrlinger, and Michael Weller, and Lars Fischer, and Agnieszka Korfel, and
January 2016, SpringerPlus,
Copied contents to your clipboard!